DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bleomycin; Device: MRI; Indocyanine green; L04AA10; OK432; Picibanil; Propranolol; RAPAMUNE; Rapamune; Rapamycin; Rapamycin dosage; SIROLIMUS; Selenium; Sildenafil; Sildenafil 20 mg tablets; Sirolimus; Sirolimus 0,1% crème; Sirolimus 1mg/mL; Sirolimus Oral Liquid Product 1mg/mL; Topical 0.1% Sirolimus; Topical Vehicle; VT30; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031180265	10/08/2016	13/03/2019	Study of bleomycin and OK-432 combined scletotherapy for LMs	Clinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformations	Lymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic lymphangioma, lymphatic malformation,;D18.1	OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBW	Fujino Akihiro	NULL	Not Recruiting	Not applicable	Not applicable	Both	21	N/A	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs031180265

10/08/2016

13/03/2019

Study of bleomycin and OK-432 combined scletotherapy for LMs

Clinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformations

Lymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic
lymphangioma, lymphatic malformation,;D18.1

OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBW

Fujino Akihiro

NULL

Not Recruiting

Not applicable

Both

N/A

Japan